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De-Qing Zhang1†, Qiang Guo2†, Jian-Hong Zhu1† and Wei-Chang Chen1*Abstract
Background: The purpose of this study was to investigate the anti-tumor effect and explore the mechanisms of
celecoxib (a selective cyclooxygenase-2 inhibitor) combined with 5-fluorouracil (5-FU) on the treatment of human
colorectal cancer in a BALB/C nude mouse subcutaneous xenograft model.
Methods: Effects of celecoxib combined with 5-FU on the proliferation of xenograft carcinoma induced by HT-29
were investigated. The apoptotic cells were detected by electron microscope and TUNEL (terminal deoxynucleotidyl
transferase dUTP nick end labeling) assay. Immunohistochemistry and Western blot were used to estimate the
expression of cytochrome C, caspase-3 and caspase-9.
Results: Compared with the control group, treatment groups showed significant inhibition of tumor growth. More
apoptotic cells existed after treatment with celecoxib combined with 5-FU. Cytochrome C, caspase-3 and caspase-9
were increased in treated groups, and more obviously in the drug combination group. Cyclooxygenase-2 (COX-2)
were decreased after treatment with celecoxib only or combined with 5-FU. And the combined group showed a
greater decrease.
Conclusions: Celecoxib combined with 5-FU could inhibit the growth of tumors in vivo by inducing apoptosis and
activation of the cytochrome C dependency apoptosis signal pathway. A decrease of COX-2 and an increase of
cytochrome C, caspase-3 and caspase-9 may be involved in this process.
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5-Fluorouracil (5-FU) is one of the most common and
effective clinical chemotherapy medications for treatment
of digestive tract tumors, with a specific set of effects.
Internally, 5-FU not only transforms into corresponding
nucleotides and helps develop an anti-tumor effect, it can
also induce apoptosis. Theoretically, 5-FU can bring about
carcinogenic cell DNA deterioration and acceleration of* Correspondence: chenweichang2012@163.com
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reproduction in any medium, provided the ortumor cell apoptosis [1,2]. Whereas 5-FU only had a single
effective rate of 24%, and approximately 31% as the
first-line drug of clinic chemotherapy on colon cancer,
the increase in dosage could cause severe toxic- and
side-effects, and gradually increasing drug resistance also
limited its dosage and therapeutic effect [3,4].
Many epidemiology data, lab studies and clinical
observations show that NSAIDs, nonsteroidal anti-
inflammatory drugs, are effective at prevention and
inhibition of digestive tract tumors, both as external and
internal treatments. Cyclooxygenase-2 (COX-2) over-
expressed is closely related to various tumors, especially
gastrointestinal tumors [5]. Related studies have shownLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of many kinds of organic tumors, including colon tumors,
while also strengthening the effectiveness of chemotherapy
treatment. At present, there are clinical reports of the
effectiveness of combining selective COX-2 inhibitors with
chemotherapy to treat digestive tract tumors; however, the
exact mechanism of the anti-tumor effect created by this
treatment is still unclear. Celecoxib, as a selective COX-2
inhibiter, holds a very good application prospect for the
prevention and treatment of colon cancer. Meanwhile, it
has been a hotspot of colon cancer research and receives
more clinical attention due to its better gastrointestinal
safety [6-8].
Celecoxib and 5-FU each have separate anti-tumor
functions. Whether or not combined application of the
two treatments can create a collaborative anti-tumor effect
is still being debated [9-11]. For this reason, this experi-
ment involves combined celecoxib and 5-FU treatment on
a subcutaneous implantation tumor model of human colon
cancer, in order to discover if such treatment does produce
a collaborative anti-tumor effect and corresponding mech-
anism. These results may aid the progress and applicability
of selective COX-2 inhibitors as a form of collaborative
clinical treatment for tumor growth, and serve as the
foundation for related future research.
Methods
Cell line and animal model
Human colon cancer HT-29 cells were purchased from
the Cellular Biological Institute of the Science Academy
of China in Shanghai and cultured in McCoy’s 5A with
10% fetal bovine serum (FBS). All cells were cultured at
37°C in humidified incubators with 5% CO2 and 95% air.
To establish the tumors in mice, HT-29 cells were
grown in culture. Five- to six-week old athymic BALB/c
nude mice (Animal Center of the Soochow University,
China) were injected with 8 × 107 HT-29 cells to activate
tumor growth. After the tumor volume reached 50 to
100 mm3, the mice were randomly divided into four
groups for further treatment as described below. This
study conforms to the Guide for the Care and Use
of Laboratory Animals published by the US National
Institute of Health (NIH Publication No. 85–23,
revised 1996) and was approved by the Moral and
Ethical Committee of the First Affiliated Hospital of
Soochow University.
5-FU and COX-2 inhibitor treatment
The selective COX-2 inhibitor, celecoxib (production NO.
639 T), was a generous gift of Pharmacia and Upjohn, Ltd.
(Suzhou, China). The control group took in purified saline,
the 5-FU group was given 5-FU (20 mg/kg), the celecoxib
group was given celecoxib (1,500 ppm, 1.5 mg/ml), and the
5-FU + celecoxib group was given the combination ofcelecoxib and 5-FU (1,500 ppm celecoxib + 20 mg/kg
5-FU). All animals started to receive drug interven-
tion after the subcutaneous xenograft model was
established. The administration method of celecoxib
was a fresh solution prepared by dissolving celecoxib
in sterilized distilled water, and the nude mice took
in the solution freely every day till the end of the
experiment. 5-FU treatment was also administered via
abdominal injection starting on the same day of
celecoxib administration, and was continued for five
days at a rate of one treatment per day. The dosage
needed for each nude mouse was calculated according
to the mouse’s weight, and fluid volume was adjusted
to be injected into the nude mice, 1 ml for each
mouse. The nude mice in the control group and the
celecoxib group were given intraperitoneal injections
upon group division for five successive days, once per
day, and the menstruum was 1 ml normal saline.
When all mice had successfully formed colorectal
tumor masses, the length (a) and width (b) of the
tumors were measured by electric vernier calipers
every four days. The approximate volume of the tumor was
calculated according to: V = a × b2/2. The nude mice were
euthanized after 28 days of observation, and the tumor
specimen was taken by dissection, and the approximate vol-
ume of the tumors was calculated. Finally, the tumor was
weighed and the tumor inhibition rate (%) = ((the average
weight of the tumors from the control group - the average
weight of tumors from the treatment group)/ the average
weight of tumors from the control group) × 100%.
Histopathology
For histological examination, the stomach, intestine, liver
and colon of the animals were excised and fixed in 10%
neutral buffered formalin after the animals were sacrificed.
Paraffin embedded sections (5 μm) were cut and stained
with hematoxlin and eosin for histological examination.
Immunohistochemisty for cytochrome C, caspase-3 and
caspase-9 protein
Xenograft tumor tissue paraffin sections underwent routine
deparaffinage, using gradient alcohol hydration, were sealed
for 15 minutes with 1% H2O2, rinsed with 0.01 mol/L PBS.
Antigens retrieval was carried out by microwave oven
heating for 15 minutes. The sections were sealed in 2%
normal goat blood serum for one hour, then, dropwise
mouse anti-human caspase-3 and caspase-9 monoclonal
first antibody (1:1,000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA), cytochrome C monoclonal antibody
(1:500; Santa Cruz Biotechnology) were added, incubated
overnight under 4°C, then a second antibody (1:200; Santa
Cruz Biotechnology) marked by HRP was added dropwise
after a phosphate-buffered saline (PBS) rinse. The tissue
was then incubated at room temperature for 2 hours,
Table 1 The volume and weight of colon tumor※
Group Volume of tumor (cm3) Weight of tumor (g)
control 0.5367 ± 0.0532 0.5924 ± 0.0612
5-FU 0.3429 ± 0.0875a 0.4276 ± 0.0629a
celecoxib 0.1947 ± 0.0386a 0.2783 ± 0.0314a
5-FU + celecoxib 0.1428 ± 0.0236a,b,c 0.1281 ± 0.0219a,b,c
Note: ※ Values represent the mean ± SD; a There were significant differences
in the volume and the weight of tumors between each treatment group
compared with the control group, P <0.05. b Compared with the 5-FU group,
the volume and the weight of tumors were dramatically lower in the 5-FU +
celecoxib group, P <0.05. C Compared with the celecoxib group, the volume
and the weight of tumors were also significantly lower in the 5-FU + celecoxib
group, P <0.05. Figure 2 The influence of 5-FU and celecoxib on tumor growth.
The anti-tumor effect on the 5-FU + celecoxib group was better
than the other groups.
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hematoxylin. The results were judged positive as was previ-
ously described [12]. The evaluation criteria were as
follows: (1) Staining intensity was evaluated and assigned a
score of 0 to 3+: 0 = negative, 1 + = weak, 2+ = moderate,
3+ = strong. (2) Immunoreactivity score was assigned based
on the proportion of positive cells over total cells
(percent positivity) ranging from 0 to 100% on a scale
of 0 to 3: 0 = 0% positive cells, 1 = 1 to 25% positive
cells, 2 = 26 to 50% positive cells, 3 = >60% positive
cells. The IHC scoring was then assigned by multiplying
the staining score and immunoreactivity score, and the
score thus ranged from 0 to 9.0.Transmission electron microscope
A total of 60 mg of xenograft tumor tissue mass was
fixed in 2.5% glutaral for no less than two hours,
prepared with saturated uranyl acetate with 70% alcohol.
After 30 minutes’ stirring, the tissue was fixed with 4%
osmic acid three times, then rinsed with phosphate
buffered saline. The tissue was re-warmed with embed-
ding material after being rinsed with 50% alcohol, then
the sample was placed in a capsule and polymerized by
heating (at 63°C for 72 h).Enteric-coated capsules were
made after 48 hours, and then apoptosis was observed
under an electron microscope.Figure 1 Comparison of tumor inhibition rate in each group.
The tumor inhibition rate i the control group, the 5-FU group, the
celecoxib group and the 5-FU + celecoxib group was 0%, 27.81%,
53.02% and 78.37%, respectively. P <0.05 among all groups.TUNEL assay
The percentage of apoptosis cells were detected by
commercially available (terminal deoxynucleotidyl trans-
ferase dUTP nick end labeling) TUNEL assay kits (XiTang
Biotechnology Corp., Shanghai, China), according to the
instructions provided by the manufacturer. The karyotin
of apoptosis nucleus was pitchy, while that of the
non-apoptosis nucleus was calamine blue. Ten high
power fields (HPF) were selected for each slice, and
the number of positive cells was counted for every
1,000 cells. The apoptosis rate (%) = number of positive
apoptosis cell/1,000 × 100%.Western blot analysis
Western blot was performed as described previously
[13]. Membranes were developed using ECL reagents
(Denville Scientific, Metuchen, NJ, USA) and exposed
to X-ray films. Mouse original first antibody caspase-9
(1:1,000; Santa Cruz Biotechnology), mouse original
first antibody caspase-3 (1:1,000; Santa Cruz Biotech-
nology) and mouse original first antibody COX-2
(1:1,000; Santa Cruz Biotechnology) were used for
Western blot analysis.Figure 3 Comparison of TUNEL positive rate in each group. The
rate of tumor apoptosis in the control group, 5-FU group, celecoxib
group and 5-FU + celecoxib group was 9.5%, 47.5%, 68.5% and
80.1%, respectively, P <0.05 among all groups.
Figure 4 Detection of apoptotic tumor cells by TUNEL assay.
TUNEL-positive cells (apoptotic cells) were stained black-brown
(magnification: × 400). There were more apoptotic cells in the 5-FU +
celecoxib group than in the other groups. (A, control group; B, 5-FU
group; C, celecoxib group; D, 5-FU + celecoxib group).
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All data were presented as means ± SD. Statistical
analysis was made by analysis of variance (ANOVA)
followed by LSD-t post-hoc test for multiple com-
parisons using SPSS16.0 (SPSS Inc., Chicago, IL, USA).
A P-value of <0.05 was considered to be statistically
significant.Figure 5 Observation of apoptotic tumor cells by fluorescence micros
×400). There were more apoptotic cells in the 5-FU + celecoxib group than
group; D, 5-FU + celecoxib group).Results
General observations
All animals successfully formed colorectal tumor masses
before being sacrificed. Both the volume and the weight
of tumors were significantly suppressed in the treated
group compared with the control group (P <0.05)
(Table 1). The tumor inhibition rate in the control
group, 5-FU group, celecoxib group and 5-FU + celecoxib
group was 0%, 27.81%, 53.02% and 78.37%, respectively,
and the combined group had the highest tumor inhibition
rate (P <0.05) (Figure 1). The effect of combined applica-
tion of celecoxib and 5-FU for the treatment of colon
carcinoma was better than for the other groups (Figure 2).
No animal showed signs of liver metastasis, hyperemia,
edema, erosion, bleeding or ulceration of the stomach and
intestine mucosa; this was confirmed by histopathology.
Apoptosis in the tumor cells
TUNEL detection showed that the number of apoptosis
cells dramatically increased in treated mice compared
with that in the control group; the rate of apoptosis was
47.5%, 68.5% and 80.1% in the 5-FU group, celecoxib
group and 5-FU + celecoxib group, respectively, while
only 9.5% in the control group (P <0.05) (Figures 3 and
4). The nucleus of apoptosis cells after dyeing in
fluorescence microscope presents green fluorescence
and was most obvious in the 5-FU + celecoxib group
(Figure 5). Electron microscopy showed that in the
treatment group the cellular outlines were extremelycope. Apoptotic cells were stained green fluorescence (magnification:
in the other groups. (A, control group; B, 5-FU group; C, celecoxib
Figure 6 Observation of apoptotic tumor cells by transmission electron microscope (Magnification: × 6000). The morphology alteration
of apoptotic tumor cells in the 5-FU + celecoxib group was more typical than that in other groups. (A, control group; B, 5-FU group; C, celecoxib
group; D, 5-FU + celecoxib group).
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nuclear membrane was intact, the nucleolar zone
completely disappeared, chromatin was aggregated,
became tight and concentrated beneath the nuclear
membrane, part of mitochondria swelled and enlarged,
the cell membrane was intact, nuclear fragmentation
existed, apoptotic bodies encapsulated by membranes
were scattered among the cells and contained residual nu-
cleus and organelles (Figure 6). The apoptosis expression
was especially typical in the 5-FU + celecoxib group, but
was not demonstrated in the control group.
Cytochrome C, caspase-3, caspase-9 and COX-2 protein
expression
Immunohistochemisty detection showed that the protein
expression of cytochrome C, caspase-9 and caspase-3 was
mainly in the apoptosis cells. In the apoptosis tumor cells,
the staining of cytochrome C, caspase-9 and caspase-3
protein positive expression were mainly cytoplasm staining;
a small part of the staining was nucleus and nuclear mem-
brane staining and brownish yellow particles. Experimental
results showed that the protein expression of cytochrome
C, caspase-9 and caspase-3 in the interference group
significantly increased compared with the control
group (P <0.05) and more obviously in the drug combi-
nation group (the 5-FU + celecoxib group) (P <0.05,
Table 2). Results were confirmed byWestern blot (Figure 7).
In the 5-FU group and the 5-FU + celecoxib group, COX-2Table 2 Expression levels of cytochrome C, caspase-3 and cas
Group Cytochrome C
control 1.7542 ± 1.1869
5-FU 3.7397 ± 1.2963a
celecoxib 5.6286 ± 1.0629 a
5-FU + celecoxib 7.9784 ± 1.1265 a,b,c
Note: ※ Values represent the mean ± SD; a There were significant differences in the
treatment group compared with the control group, P <0.05. b Compared with the 5
was significantly higher in the 5-FU + celecoxib group, P <0.05. C Compared with th
caspase-3 was also significantly higher in the 5-FU + celecoxib group, P <0.05.expression was more suppressed than that in the control
group and celecoxib group. Also COX-2 expression was
inhibited more obviously after combined drug treatment.
While between the control group and the 5-FU group no
obvious differences were observed (Figure 8).
Discussion
Colon cancer is one of the common malignant tumors
in the digestive system, and the early diagnosis of colon
cancer is very difficult. The main therapeutic methods of
treating colon cancer are still radiotherapy and chemo-
therapy. As the first-line drug of clinical chemotherapy
for colon cancer, 5-FU has not only poor efficacy, but
also has significant side effects [3,4]. A therapeutic alli-
ance could possibly improve the effect of chemotherapy
on these tumors, and meanwhile reduce the adverse
reaction of using a single drug.
Attention has recently been paid to un-cytotoxic drugs
in tumor therapy research, and there have been many
developments in the research of the COX-2 inhibitor’s
effects on inhibiting tumor growth [14-17]. Celecoxib
is a kind of highly selective COX-2 inhibitor, and has
stronger pharmacologic actions and less adverse reactions
compared with traditional NSAIDS [18]. Recent research
has also found that selective COX-2 inhibitors can
enhance the sensitivity of tumor cells to many kinds of
chemotherapeutic drugs, thus reducing the IC50 of
chemotherapeutic drugs by nearly 70% [19]. By usingpase-9※
Caspase-9 Capase-3
2.1837 ± 1.3627 1.7562 ± 1.2761
3.0527 ± 1.0667a 2.9242 ± 1.6728a
5.9782 ± 1.2869 a 6.7197 ± 1.1869 a
7.7281 ± 1.0691 a,b,c 7.9942 ± 1.0014 a,b,c
protein expression of cytochrome C, caspase-9 and caspase-3 between each
-FU group, the protein expression of cytochrome C, caspase-9 and caspase-3
e celecoxib group, the protein expression of cytochrome C, caspase-9 and
Figure 7 Detection of protein expression of cytochrome C, caspase-3 and caspase-9 by Western blot. The protein expression of
cytochrome C, caspase-9 and caspase-3 in the 5-FU + celecoxib group was significantly stronger than that in other groups.
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observing the effect of the selective COX-2 inhibitor
nimesulide on various anti-tumor drugs (including DDP
and VP16), Zheng [20] found that there were synergistic
effects when nimesulide was used in combination
with cytotoxic chemotherapeutic drugs. Our research
indicated that the apoptotic morphology change was
most significant and had the highest tumor inhibition
rate in the drug combination group.
In order to further investigate the mechanism of
celecoxib’s chemotherapy sensitization, we examined the
protein expression of cytochrome C, caspase-9 and cas-
pase-3. Our results showed that cytochrome C, caspase-9
and caspase-3 were up-regulated after treatment with ce-
lecoxib and 5-FU, especially in combination. This reveals
that the combined use of two drugs had synergistic, anti-
tumor effects, whose mechanism of action may be
associated with the activation of cytochrome C-dependent
apoptosis signal pathway. Some papers also reported that
NSAIDs, such as indomethacin and sulindac, could
suppress the transmembrane protein ATP dependent efflux
pump (multidrug resistance associated protein, MRP) p2
glucoprotein related to chemotherapeutic efflux, and
inhibit the activity of glutathione transferase. Through
these pathways, NSAIDs could inhibit chemotherapeutic
efflux and decrease the multiple drug resistance of tumor
cells against chemotherapeutics [21]. In addition to animal
experiments, there were some reports of the Phase I andFigure 8 Detection of protein expression of COX-2 by Western blot. I
suppressed more than in the control group and celecoxib group. COX-2 ex
drug treatment.Phase II clinical trials on celecoxib in combination with
chemotherapy treatment for cancer [22-24]. Relevant test
results indicated celecoxib has synergistic anti-tumor
effects. A therapeutic alliance could reduce the dose and
the adverse reaction of chemotherapy drugs. Some clinical
research proved that combined application of celecoxib
could effectively improve the three-year survival rate of
patients with advanced colorectal cancer [25,26].
In our research, we also found that celecoxib combined
with 5-FU could inhibit COX-2 protein expression. In
recent years, much evidence has documented that COX-2
could up-regulate apoptosis suppressor genes’ bcl-2 levels
by activating MAP kinase and bcl-2 could dramatically
inhibit activation of cytochrome C pathway [27,28]. Our
experiment showed that the synergistic anti-tumor effect
with administration of 5-FU and celecoxib is not only
related to improving the chemotherapy sensitization of
5-FU, but also may be associated with the effect by which
5-FU can enhance the ability of celecoxib to inhibit protein
expression of COX-2. The chemotherapy agent 5-FU,
which has been used against cancer for about 40 years,
acted in several ways, but principally as a thymidylate
synthase inhibitor. Interrupting the action of this enzyme
blocked synthesis of the pyrimidine thymidine, which was a
nucleoside required for DNA replication [2]. Administra-
tion of 5-FU caused a scarcity in dTMP, so rapidly dividing
cancerous cells undergo cell death via thymineless death.
According to the results of this experiment, we speculaten the 5-FU group and 5-FU + celecoxib group, COX-2 expression was
pression was inhibited more obviously after the combined
Zhang et al. World Journal of Surgical Oncology 2013, 11:16 Page 7 of 8
http://www.wjso.com/content/11/1/16that 5-FU can promote the effect that celecoxib
inhibits the protein expression of COX-2 by regulating
the gene expression.
Current research has shown that NSAIDs, including
selective COX-2 inhibitors, could augment the sensitivity
of many kinds of tumors toward chemotherapeutics, but
its mechanism was still unknown, and it may involve
multiple molecular mechanisms. Our experiment utili-
zed a combination to implement drug interference based
on the model of xenograft tumors in nude mice, and
proved that when celecoxib and 5-FU are used in com-
bination they had synergic anti-tumor effects. Suppres-
sion of COX-2 and activation of the apoptosis signal
might be related to these processes.
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